Narazaciclib (ON123300) is a second-generation, orally bioavailable, and clinical-stage CDK4/6 inhibitor (CDKi) that may trigger cell cycle arrest and significant tumor growth inhibition (TGI) in BTKi-resistant MCL [109]. This evidence concerns the gene IBTK and mantle cell lymphoma.